Michael Ehrenstein, MD
Professor of Rheumatology
University College Hospital
University College of London School of Medicine
London, UK
When are you inclined to use combination therapy with a DMARD and biologic, and when is monotherapy with a DMARD alone a reasonable strategy?
Why has IL-6 emerged as an important target for treating RA and through what mechanisms does inhibition of IL-6 affect the pathogenesis of RA?
How do TNFIs and IL-6 inhibitors compare as far as their effectiveness when used as monotherapy?
How do TNFIs and IL-6 inhibitors compare as far as their effectiveness when used as monotherapy?How does one optimize the safety profile of IL-6 inhibitors?
How does one optimize the safety profile of IL-6 inhibitors?
What percentage of patients who have had an inadequate response to an initial biologic agent such as TNF seem to respond to biologics with a different MOA, such as an IL-6 inhibitor?
Are there markers in RA that suggest a more progressive or aggressive disease course or that will predict non-responsiveness?
Can we use biomarkers in any way to help align therapy in RA with a specific therapeutic agent?
Can we use biomarkers in any way to help align therapy in RA with a specific therapeutic agent?Do you modify your dose of IL-6 inhibitor if you encounter elevations in LDL level?
Do you modify your dose of IL-6 inhibitor if you encounter elevations in LDL level?